FLAG-GO vs FLAG-Ida regimen leads to better relapse-free survival in CBF acute myeloid leukaemia
16 Dec 2019
byStephen Padilla
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.